BidaskClub upgraded shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) from a sell rating to a hold rating in a research note released on Saturday.

Other equities research analysts also recently issued research reports about the company. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a buy rating in a research report on Friday, July 7th. ValuEngine raised Inovio Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, June 2nd. Zacks Investment Research raised Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 price objective on the stock in a research report on Tuesday, July 11th. Piper Jaffray Companies raised Inovio Pharmaceuticals from a neutral rating to an overweight rating and set a $14.00 price objective on the stock in a research report on Thursday, June 8th. Finally, Maxim Group raised their price objective on Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in a research report on Wednesday, May 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Inovio Pharmaceuticals has an average rating of Buy and a consensus price target of $19.80.

Inovio Pharmaceuticals (NASDAQ INO) opened at 6.00 on Friday. Inovio Pharmaceuticals has a 52 week low of $5.28 and a 52 week high of $9.86. The company has a 50-day moving average of $5.69 and a 200-day moving average of $6.69. The company’s market cap is $541.36 million.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The business’s revenue for the quarter was up 229.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) earnings per share. On average, equities analysts expect that Inovio Pharmaceuticals will post ($0.92) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) Lifted to “Hold” at BidaskClub” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/13/inovio-pharmaceuticals-inc-ino-lifted-to-hold-at-bidaskclub.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Inovio Pharmaceuticals by 4.2% in the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after acquiring an additional 129,164 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after acquiring an additional 793,306 shares in the last quarter. Northern Trust Corp boosted its holdings in Inovio Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after acquiring an additional 24,366 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after acquiring an additional 62,045 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after acquiring an additional 11,765 shares in the last quarter. 24.83% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Stock Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.